TTKHLTCARE NSI Week ended 07 Aug 2026

Weekly Investor Report

TTK Healthcare Limited · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 1,085 INR
6.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 18.4% above the Trend Line and sits at 72.6% of its 52-week range. The latest completed week returned 6.3%, after a 19.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.

Setup score 67 out of 100
Latest Close 1,085 INR 7 Aug 2026
1W Return 6.3% latest completed week
4W Return 19.1% short-term follow-through
12W Return 20.9% quarterly tape
Trend Breadth 3.8% 2 of 52 weeks active
Volume Ratio 4.1x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.3% Latest completed week; four-week move 19.1%. Indicator stack 9/89 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 18 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 18.4% above the Trend Line and sits at 72.6% of its 52-week range. The latest completed week returned 6.3%, after a 19.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 4.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4012-week average 0.24

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.40Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 19.1% over four weeks, 20.9% over 12 weeks, and -5.0% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W6.3%
4W19.1%
12W20.9%
26W14.0%
52W-5.0%
Active trend streak2 weeks
Active weeks in one year2
Trend breadth3.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.73Latest activity-pressure read.
Pressure change103.2%Four-week change in activity pressure.
Leadership9.05Latest relative-leadership reading.
RS change207.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value39/100Relative valuation strength. Underlying universe rank 62; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum30/100Medium-term price momentum. Underlying universe rank 71; rank 1 is best.
Growth18/100Revenue and earnings growth. Underlying universe rank 83; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework4/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
24.9x
Price divided by trailing earnings.
Price / sales
1.8x
Market value relative to trailing revenue.
EV / EBITDA
16.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
53.4%
Gross profit retained from each unit of revenue.
Operating margin
2.9%
Operating profit retained from revenue.
Free-cash-flow margin
-3.2%
Free cash flow generated from revenue.
Return on invested capital
1.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
7.1%
Latest one-year revenue growth.
EPS growth
-19.6%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.9%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 18 relevant articles.

0 positive · 17 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-10.8%Distance below the 52-week high.
13-week volatility3.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+12.3%Week of 10 Apr.
Worst week-5.8%Week of 13 Mar.
Latest week+6.3%Week of 7 Aug.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses13
Sharp losses2
Recent vol3.7%13-week weekly-return volatility.
Base vol3.3%52-week weekly-return volatility.
Up/down split18/34Count of positive and negative weeks in the 52-week window.
Average skew3.4% / -1.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape59/100

Trend, activity pressure, participation, and risk combine to a 59/100 tape read.

 Indicator analysis46/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 3/12.

Activity pressure 0.40; No reversal markers Factors21/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 59; Small Cap Core rank 34 SVQF4/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 1520.0 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 18 relevant articles.

Prestige Consumer Healthcare Q1 Earnings Call Highlights Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261,085 INR6.3%916.5 INR1,251 INR1.739.05289.6KOn
31 Jul 20261,020 INR-2.6%913.7 INR1,251 INR1.573.20212.3KOn
24 Jul 20261,047 INR6.8%913.9 INR1,252 INR1.348.21165.2KOff
17 Jul 2026980.5 INR7.6%913.6 INR1,253 INR1.07-1.42189.8KOff
10 Jul 2026911.1 INR-0.3%915.8 INR1,255 INR0.85-8.4617.6KOff
3 Jul 2026913.5 INR0.0%920.7 INR1,257 INR0.69-9.072.6KOff
26 Jun 2026913.4 INR-0.7%926.5 INR1,259 INR0.64-8.910Off
19 Jun 2026920.0 INR4.3%933.2 INR1,261 INR0.59-8.5916.0KOff
12 Jun 2026882.0 INR-3.5%940.1 INR1,263 INR0.49-11.40972Off
5 Jun 2026914.2 INR2.5%948.6 INR1,266 INR0.50-7.741.5KOff
29 May 2026891.8 INR0.3%956.6 INR1,268 INR0.51-11.077.4KOff
22 May 2026889.5 INR-0.9%966.1 INR1,270 INR0.52-12.387.2KOff
15 May 2026897.3 INR-3.2%974.8 INR1,272 INR0.52-11.876.5KOff
8 May 2026926.8 INR2.5%983.8 INR1,274 INR0.39-11.379.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context